Mastoid surgery publication overviews

January 12, 202110:32

This quarter we highlight solutions for mastoid surgery as the Bonalive indication of the quarter. We will share publication overviews with you below.

1. Anatomical, functional and quality-of-life results for mastoid and epitympanic obliteration with bioactive glass s53p4: a prospective clinical study
We start off with a publication overview of an article by Bernardeschi et al (2017). Mastoid and epitympanic obliterations were performed using S53P4 bioactive glass and the cases were analysed 1 year post op. The study shows that canal-wall-down or canal-wall-up tympanoplasties obliterated with S53P4 is effective in both primary and revision surgery. The anatomical and functional results appear to be well correlated with patient experience and to the improvement in quality of life. Read the abstract here.


2. Mastoid obliteration with S53P4 bioactive glass in cholesteatoma surgery
The second publication overview is of an article by de Veij Mestdagh et al (2017). Patients underwent either canal wall up or canal wall down tympanomastoidectomy with mastoid obliteration using S53P4 bioactive glass. The publication concludes that S53P4 bioactive glass is a safe and effective obliteration material in cholesteatoma surgery. Access the publication here.


3. Bioactive glass granules for mastoid and epitympanic surgical obliteration: CT and MRI appearance
The third and last publication overview is by Bernardeschi et al (2019). The article concludes that radiological follow-up of patients operated on with mastoid and epitympanic obliteration using S53P4 bioactive glass (BG) granules is effective using both HRCT and MRI. A cholesteatoma and/or other potential complications could easily be detected due to the specific radiological appearance of the BG granules. Access the publication here.